Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now HKSE - Delayed Quote • HKD Zai Lab Limited (9688.HK) Follow Add holdings 25.200 +0.700 +(2.86%) At close: May 2 at 4:08:23 PM GMT+8 All News Press Releases SEC Filings Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 SHANGHAI & CAMBRIDGE, Mass., April 25, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an innovative anti-PD-1/ interleukin-12 (IL-12) immunocytokine for cancer immunotherapy, during poster sess Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting SHANGHAI & CAMBRIDGE, Mass., April 23, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company’s potential first-in-class and best-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Mee Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors SHANGHAI & CAMBRIDGE, Mass., April 21, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to re All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025 SHANGHAI & CAMBRIDGE, Mass., April 14, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2025 financial results and provide recent corporate updates on May 8, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout We recently published a list of 10 Stocks Insiders Sold in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other stocks that insiders sold in April after Trump’s tariff rollout. Last week, President Donald Trump signed an executive order imposing […] Spotlight On High Growth Tech Stocks In The US March 2025 Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 5.8% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks requires looking for companies that not only show robust revenue potential but also demonstrate resilience and adaptability in fluctuating market conditions. Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting SHANGHAI & CAMBRIDGE, Mass., March 26, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research (A Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025? We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […] Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.” Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. “Treatment options for patients experiencing recurrence or metastasis after initial treatment are limited. TIVDAK, the Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer SHANGHAI & CAMBRIDGE, Mass., March 12, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Zai Lab Announces Participation in Investor Conferences in March 2025 SHANGHAI & CAMBRIDGE, Mass., March 03, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in March 2025: Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates Investors in Zai Lab Limited ( NASDAQ:ZLAB ) had a good week, as its shares rose 2.5% to close at US$34.64 following... Zai Lab Full Year 2024 Earnings: Beats Expectations Zai Lab ( NASDAQ:ZLAB ) Full Year 2024 Results Key Financial Results Revenue: US$399.0m (up 50% from FY 2023). Net... Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability Zai Lab Ltd (ZLAB) reports a 66% revenue surge in Q4 2024, with strategic advancements paving the way for profitability by late 2025. China Biotech's Sales Jump 66% But Bottom Line Misses Views Zai Lab pulled back after the biopharmaceutical reported fourth-quarter results. The biotech is building a cup base. Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates SHANGHAI & CAMBRIDGE, Mass., February 27, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates. Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts? We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best performing mid cap stocks to buy according to analysts. On February 7, Simeon Hyman, Global Investment Strategist at […] Performance Overview Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) Return 9688.HK HANG SENG INDEX (^HSI) YTD +20.00% +12.19% 1-Year +84.48% +23.60% 3-Year -23.52% +6.71%